Loading
BioAtla, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Jan 2024.
BioAtla, Inc.: what insiders have been doing
BioAtla, Inc., founded in 2007, is a Healthcare & Pharma company based in San Diego, United States. Its directors and officers file their transactions with SEC (Form 4). 4 insiders have disclosed 17 filings since 18 October 2025.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Compared with its exchange (5,816 companies, median 19 filings), a count of 17 filings is below the norm. Over the whole record (from 2021), the tally stands at 14 purchases and 26 sales.
No insider has bought BioAtla, Inc. shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
242
Thresholds
n/a
Buy Volume
€688,178
14 ops. · all time
Sell Volume
€3M
26 ops. · all time
Since the insiders bought
- -74.8%Entry US$100.00 · Close at T+365 US$25.25
- -69.2%Entry US$112.50 · Close at T+365 US$34.60
- -41.1%Entry US$101.00 · Close at T+365 US$59.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.36
Analyst consensus
Income statement
RevenueUS$2M
EBITDA-US$58.9M-2947% margin
Net income-US$59.6M-2980.4% margin
Valuation
Beta0.70
Balance sheet & cash
Market capUS$2.3M
Total debtUS$6.2M
Free Cash Flow-US$48.2M
Profitability & ownership
ROA-105.9%
% insiders5.4%
% institutions21.4%
Last declaration on 5 June 2026
Declarations242 total
134 shares@ US$3.930.0082% mcap0.1% of flowCommon StockSEC:0001193125-26-259689:1
82 shares@ US$3.930.0050% mcap0.2% of flowCommon StockSEC:0001193125-26-259699:1
259 shares@ US$3.930.016% mcap0.0% of flowCommon StockSEC:0001193125-26-259702:1
360 shares@ US$0.1690.0% of flowCommon StockSEC:0001193125-26-259689:0
175 shares@ US$0.1690.0% of flowCommon StockSEC:0001193125-26-259699:0
639 shares@ US$0.1680.0% of flowCommon StockSEC:0001193125-26-259702:0
240,000 shares0Common StockSEC:0001193125-26-104136:0
240,000 shares0Common StockSEC:0001193125-26-104132:0
430,000 shares0Common StockSEC:0001193125-26-104134:0
7,728 shares@ US$0.2470.1% of flowCommon StockSEC:0001193125-26-085971:0
3,140 shares@ US$0.2470.2% of flowCommon StockSEC:0001193125-26-085966:0
1,802 shares@ US$0.2470.2% of flowCommon StockSEC:0001193125-26-085970:0
2,729 shares@ US$0.2470.2% of flowCommon StockSEC:0001193125-26-085968:0
2,371 shares@ US$0.9040.5% of flowCommon StockSEC:0001193125-25-304178:0
2,729 shares@ US$0.9040.6% of flowCommon StockSEC:0001193125-25-304173:0
6,347 shares@ US$0.9040.2% of flowCommon StockSEC:0001193125-25-304171:0
1,566 shares@ US$0.9040.7% of flowCommon StockSEC:0001193125-25-304170:0
6,347 shares@ US$0.45550.1% of flowCommon StockSEC:0000950170-25-112618:0
1,566 shares@ US$0.45550.4% of flowCommon StockSEC:0000950170-25-112616:0
2,729 shares@ US$0.45550.3% of flowCommon StockSEC:0000950170-25-112615:0
2,371 shares@ US$0.45550.3% of flowCommon StockSEC:0000950170-25-112614:0
23,500 shares0Common StockSEC:0000950170-25-088065:0
23,500 shares0Common StockSEC:0000950170-25-088064:0
23,500 shares0Common StockSEC:0000950170-25-088063:0
23,500 shares0Common StockSEC:0000950170-25-088062:0
25 of 242 declarations
About BioAtla, Inc.
BioAtla, Inc. is a U.S.-listed biotechnology company trading on the Nasdaq (ticker: BCAB) and headquartered in San Diego, California, United States. For French-speaking investors, it is best viewed as a clinical-stage oncology biotech rather than a commercial pharmaceutical group: BioAtla is still focused on research, clinical development, and strategic partnering, rather than on broad product sales. The company’s core differentiation is its proprietary CAB, or Conditionarily Active Biologic, platform, designed to create highly selective antibody therapeutics that are activated preferentially in the tumor microenvironment. In theory, this approach aims to improve efficacy while reducing the off-tumor toxicity that often limits conventional cancer antibodies.
BioAtla traces its corporate roots to BioAtla, LLC, and in July 2020 it converted into a Delaware corporation under the name BioAtla, Inc., a structure better aligned with public-market financing and governance. Since then, the company has remained focused on building a pipeline in solid tumors, with an emphasis on next-generation antibody drug conjugates (ADCs) and T-cell engagers (TCEs). These are among the most competitive areas in modern oncology, where large pharma groups, mid-cap biotechs, and well-funded private companies are all competing for clinical proof of concept and licensing value.
Read moreShow less
BioAtla’s strategic positioning rests on science-based differentiation rather than scale. Its platform is intended to deliver more selective therapeutics, and management has repeatedly framed the business around the potential of its CAB technology to produce better safety profiles and novel tumor-targeted mechanisms. The company has highlighted programs such as BA3011, a CAB-enabled ADC targeting ROR2, and BA3182, a CAB-based T-cell engager targeting EpCAM. BioAtla has also discussed CAB-Nectin4-TCE progress in its recent corporate updates. As is typical for an early-stage oncology developer, the key value drivers are clinical data readouts, regulatory alignment, and partnering opportunities.
Geographically, BioAtla is international in footprint: its operations are centered in San Diego, California, with contractual operations in Beijing, China. That global setup reflects both scientific collaboration and the realities of biotech development across multiple regions. In recent announcements, the company said it had begun a formal process to evaluate strategic options to monetize assets, including potential sales, licensing transactions, and partnerships, while also implementing a major restructuring to reduce operating expenses and extend its cash runway. It has also emphasized ongoing clinical work and partnership discussions around its lead assets. Overall, BioAtla remains a high-risk, event-driven Nasdaq biotechnology name whose investment case depends on clinical execution, deal-making, and financing discipline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
